XML 42 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. The accounting policies of the segments are substantially the same as those described in Note 2 of the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020. Segment net sales and segment operating income are based on internally derived standard foreign exchange rates, which may differ from year to year, and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest income, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment and,
therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2021202020212020
Segment Net Sales    
United States$753.3 $662.0 $2,223.7 $1,845.6 
Europe268.9 241.5 806.1 695.9 
Japan126.2 109.9 384.6 325.0 
Rest of World136.1 115.2 393.6 323.4 
Total segment net sales$1,284.5 $1,128.6 $3,808.0 $3,189.9 
Segment Operating Income    
United States$527.4 $453.8 $1,544.1 $1,264.0 
Europe140.6 124.2 426.5 356.2 
Japan83.7 69.2 258.3 209.9 
Rest of World49.5 35.6 145.2 105.2 
Total segment operating income$801.2 $682.8 $2,374.1 $1,935.3 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2021202020212020
Net Sales Reconciliation    
Segment net sales$1,284.5 $1,128.6 $3,808.0 $3,189.9 
Foreign currency25.7 12.3 94.8 4.7 
Consolidated net sales$1,310.2 $1,140.9 $3,902.8 $3,194.6 
Pre-tax Income Reconciliation    
Segment operating income$801.2 $682.8 $2,374.1 $1,935.3 
Unallocated amounts:    
Corporate items(413.6)(331.9)(1,178.7)(1,005.6)
Intellectual property litigation expenses, net(4.7)(8.4)(13.5)(400.8)
Change in fair value of contingent consideration liabilities(1.1)9.0 106.0 (8.4)
Foreign currency8.5 6.3 28.0 25.7 
Consolidated operating income390.3 357.8 1,315.9 546.2 
Non-operating income 0.6 6.5 9.8 14.4 
Consolidated pre-tax income$390.9 $364.3 $1,325.7 $560.6 
Enterprise-wide Information
(in millions)

The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2021202020212020
Net Sales by Geographic Area    
United States$753.2 $662.0 $2,223.6 $1,845.6 
Europe291.1 253.8 880.9 707.8 
Japan125.9 113.9 390.0 330.7 
Rest of World140.0 111.2 408.3 310.5 
$1,310.2 $1,140.9 $3,902.8 $3,194.6 
Net Sales by Major Product Area    
Transcatheter Aortic Valve Replacement$857.8 $744.6 $2,551.0 $2,081.1 
Transcatheter Mitral and Tricuspid Therapies22.3 12.1 60.7 28.7 
Surgical Structural Heart217.4 203.3 667.8 557.6 
Critical Care212.7 180.9 623.3 527.2 
$1,310.2 $1,140.9 $3,902.8 $3,194.6 

 September 30, 2021December 31, 2020
Long-lived Tangible Assets by Geographic Area  
United States$1,132.9 $1,084.3 
Europe203.8 192.7 
Japan14.6 20.4 
Rest of World330.9 311.0 
$1,682.2 $1,608.4